ArticlePloS one2026
Tuberculosis disease burden trends, drivers, and projections to 2050 in China and the wider Central Asian region, 1990-2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a leading infectious killer, with high burden concentrated in China and wider Central Asia. Integrated long-term trend analysis and forecasting for this region are scarce. We aimed to quantify TB burden trends, drivers, inequalities, and 2050 projections across China and wider Central Asia (1990-2023).
methodsWe used Global Burden of Disease 2023 data to estimate age-standardized incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Joinpoint, age-period-cohort, decomposition, and Bayesian APC models were applied. Socioeconomic inequalities were assessed via Socio-demographic Index (SDI) and Concentration Index.
resultsChina achieved steep declines in age-standardized mortality (-94.2%) and DALYs (-92.4%), driven by epidemiological gains offsetting population growth and aging. Central Asia improved moderately but heterogeneously; population growth diluted gains, with Tajikistan showing rising absolute burden. TB burden correlated negatively with SDI; socioeconomic inequality fell markedly, especially for mortality (-69.0%), but persisted among low-SDI groups. By 2050, model projections suggest that mortality targets may be achievable under current trends, although uncertainty remains substantial.
conclusionsChina has undergone a substantial TB epidemiological transition characterized by marked declines in mortality and DALYs. Targeted interventions-latent TB treatment in China, accelerated case finding and cross-border collaboration in Central Asia-and strengthened regional cooperation are critical to advance regional TB elimination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.